EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non‑small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy

Guo,Nannan; Zhang,Wen; Zhang,Baoshi; Li,Yingjie; Tang,Jian; Li,Shaojun; Zhao,Yingnan; Zhao,Yunlong; Xia,Hui; Yu,Changhai

doi:10.3892/mco.2015.611

EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non‑small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy

Authors:
- Nannan Guo
- Wen Zhang
- Baoshi Zhang
- Yingjie Li
- Jian Tang
- Shaojun Li
- Yingnan Zhao
- Yunlong Zhao
- Hui Xia
- Changhai Yu
View Affiliations

Affiliations: Medical School of Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Thoracic‑Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
Published online on: July 21, 2015 https://doi.org/10.3892/mco.2015.611
Pages: 1123-1128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Personalizing medicines has refined the traditional treatments for non-small-cell lung cancer (NSCLC). In the present study, efforts towards personalizing delivery of care based on the status of EGFR and K‑RAS mutations, and mRNA expression levels of ERCC1, TUBB3, TYMS, RRM1 and EGFR by choosing appropriate treatments for 52 patients with NSCLC were discussed. Among these 52 NSCLC patients, there were 14 patients treated with gefitinib. Ten patients with EGFR exon 21 point mutations or exon 19 deletions had better treatment outcomes following gefitinib treatment (71.4%). There were 38 patients treated with platinum‑based chemotherapy. Docetaxel‑platinum based chemotherapy was chosen as the first‑line treatment when the patients had low or median ERCC1/TUBB3 expression and gemcitabine‑platinum based chemotherapy was chosen when the patients had low or median ERCC1/RRM1 expression. In total, 26 cases had mRNA expression levels of ERCC1/TUBB3 or ERCC1/RRM1 that could be used to predict the treatment outcomes of chemotherapy (68.4%). The present results indicated that the mutation status of EGFR, as well as the mRNA expression levels of ERCC1, TUBB3 and RRM1, could be used as predictors of the response to gefitinib or chemotherapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jazieh AR, Bamefleh H, Demirkazik A, et al: Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 8:(Sul 3). S16–S21. 2010.PubMed/NCBI
3	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
4	Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 11:5878–5885. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gazdar AF and Minna JD: Inhibition of EGFR signaling: All mutations are not created equal. PLoS Med. 2:e3772005. View Article : Google Scholar : PubMed/NCBI
6	Hirsch FR: EGFR: a prognostic and/or a predictive marker? J Thorac Oncol. 1:395–397. 2006. View Article : Google Scholar : PubMed/NCBI
7	Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI
8	Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI
9	Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
10	Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer. 69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
11	Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, et al: Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 64:326–333. 2009. View Article : Google Scholar : PubMed/NCBI
12	Burkhart CA, Kavallaris M and Band Horwitz S: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
13	Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, et al: Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 3:1112–1118. 2008. View Article : Google Scholar : PubMed/NCBI
14	Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, et al: Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325. 2004. View Article : Google Scholar : PubMed/NCBI
15	Travis W, Colby TV and Corrin B: Histologic Typing of Tumors of Lung and Pleura: World Health Organization International Classification of Tumors. 3rd. Springer Verlag; New York, NY: 1999
16	Li G, Luo X, He J, Zhu Z, Yu G, Qin H, Zeng T, Liu Z, Wu S, Xu J, et al: A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med. 49:191–195. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Liu ZD, Zhao LM, Du CX, Xi XM, Mi YL, Peng Y, Li WG, Cheng F, Zhang XR, et al: Individualized treatment of NSCLC: From research to clinical practice. Neoplasma. 60:538–545. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
19	Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 24:5034–5042. 2006. View Article : Google Scholar : PubMed/NCBI
21	Vadakara J and Borghaei H: Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med. 5:113–123. 2012.PubMed/NCBI